MY144492A - Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types - Google Patents

Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types

Info

Publication number
MY144492A
MY144492A MYPI20034868A MYPI20034868A MY144492A MY 144492 A MY144492 A MY 144492A MY PI20034868 A MYPI20034868 A MY PI20034868A MY PI20034868 A MYPI20034868 A MY PI20034868A MY 144492 A MY144492 A MY 144492A
Authority
MY
Malaysia
Prior art keywords
hpv
protection against
virus
particles
human papillomavirus
Prior art date
Application number
MYPI20034868A
Other languages
English (en)
Inventor
Gary Dubin
Bruce Innis
Moncef Mohamed Slaoui
Martine Anne Cecile Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MY144492A publication Critical patent/MY144492A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MYPI20034868A 2002-12-20 2003-12-18 Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types MY144492A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20

Publications (1)

Publication Number Publication Date
MY144492A true MY144492A (en) 2011-09-30

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20034868A MY144492A (en) 2002-12-20 2003-12-18 Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types

Country Status (28)

Country Link
US (2) US20060251676A1 (mber)
EP (1) EP1572233B1 (mber)
JP (1) JP5475939B2 (mber)
KR (3) KR101361769B1 (mber)
AP (1) AP2005003347A0 (mber)
AR (1) AR042530A1 (mber)
AT (1) ATE503492T1 (mber)
AU (1) AU2003293942B2 (mber)
BE (3) BE2015C068I2 (mber)
BR (1) BR0317544A (mber)
CA (1) CA2510457C (mber)
CY (1) CY1111552T1 (mber)
DE (1) DE60336581D1 (mber)
DK (1) DK1572233T3 (mber)
EA (2) EA200701633A1 (mber)
EC (1) ECSP055869A (mber)
IL (1) IL169085A (mber)
IS (1) IS2811B (mber)
MA (1) MA27581A1 (mber)
MX (1) MXPA05006764A (mber)
MY (1) MY144492A (mber)
NO (1) NO20052846L (mber)
NZ (1) NZ540811A (mber)
OA (1) OA13147A (mber)
PL (1) PL215257B1 (mber)
PT (1) PT1572233E (mber)
TW (1) TWI349557B (mber)
WO (1) WO2004056389A1 (mber)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
CA2606092A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
AR053715A1 (es) * 2005-04-26 2007-05-16 Glaxosmithkline Biolog Sa Vacuna multivalente de vph
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
US9428555B2 (en) 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
EP2403507B1 (en) * 2009-03-05 2018-02-21 McCloskey, Jenny Colleen Treatment of infection
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
CN107001430A (zh) 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
US20180153985A1 (en) * 2015-06-02 2018-06-07 Terumo Kabushiki Kaisha Adjuvant composition containing aluminum and vaccine composition containing the same
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
WO2019173465A1 (en) * 2018-03-06 2019-09-12 Intrexon Corporation Human papillomavirus vaccines and uses of the same
BR112020024699A2 (pt) * 2018-06-04 2021-03-09 Xiamen University Mutante da proteína l1 do papilomavírus humano tipo 18
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
ES2572628T3 (es) 1997-09-05 2016-06-01 Medimmune, Inc. Método in vitro para desmontaje/remontaje de partículas análogas al virus del papiloma humano (VLP)
DE60040727D1 (de) * 1999-02-05 2008-12-18 Merck & Co Inc Menschliche papillomavirus impfstoff-formulierungen
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
DK1296711T3 (da) * 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus

Also Published As

Publication number Publication date
KR20120123616A (ko) 2012-11-08
EP1572233A1 (en) 2005-09-14
KR20120118087A (ko) 2012-10-25
MXPA05006764A (es) 2005-09-08
EP1572233B1 (en) 2011-03-30
JP5475939B2 (ja) 2014-04-16
IS2811B (is) 2012-11-15
CA2510457A1 (en) 2004-07-08
HK1085378A1 (en) 2006-08-25
DE60336581D1 (de) 2011-05-12
BE2015C069I2 (mber) 2024-08-08
AU2003293942A1 (en) 2004-07-14
NO20052846L (no) 2005-07-13
CY1111552T1 (el) 2015-08-05
IL169085A (en) 2014-04-30
EA200701633A1 (ru) 2007-12-28
NZ540811A (en) 2007-03-30
EA200500834A1 (ru) 2006-02-24
US20050287161A1 (en) 2005-12-29
ATE503492T1 (de) 2011-04-15
TW200423957A (en) 2004-11-16
KR20050086924A (ko) 2005-08-30
US20060251676A1 (en) 2006-11-09
DK1572233T3 (da) 2011-06-27
IS7885A (is) 2005-06-09
AP2005003347A0 (en) 2005-06-30
PL215257B1 (pl) 2013-11-29
OA13147A (en) 2006-12-13
CA2510457C (en) 2011-12-06
WO2004056389A1 (en) 2004-07-08
ECSP055869A (es) 2005-09-20
BE2015C067I2 (mber) 2024-08-08
JP2006512413A (ja) 2006-04-13
KR101361769B1 (ko) 2014-02-10
AU2003293942B2 (en) 2009-12-10
PT1572233E (pt) 2011-06-07
EA009179B1 (ru) 2007-12-28
TWI349557B (en) 2011-10-01
BE2015C068I2 (mber) 2024-08-08
AR042530A1 (es) 2005-06-22
MA27581A1 (fr) 2005-10-03
IL169085A0 (en) 2007-07-04
PL377710A1 (pl) 2006-02-06
BR0317544A (pt) 2005-11-22

Similar Documents

Publication Publication Date Title
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
AP1872A (en) Virus-like particles of human papillomavirus.
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
IL202978A0 (en) West nile virus vaccine
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
FR15C0084I2 (fr) Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
HUS1500061I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
WO2005023849A3 (en) Antigenic peptides of rabies virus and uses thereof
WO2005062739A3 (en) S-allylmercaptocysteine prodrugs and methods of treatment
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
UA85377C2 (ru) Применение композиции, содержащей вирусоподобные частички hpv16 і hpv18 при приготовлении медикамента для профилактики инфекции и/или болезни, вызванной группой hpv онкогенных типов, способы индуцирования иммунной реакции, профилактики инфекции и/или болезни, профилактики в популяции субъектов инфекции вызванных одной или несколькими группами онкогенных типов hpv, вакцинная композиция, которая включает hpv16 і нр18
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck
MX2007013475A (es) Vacuna.
TW200716169A (en) Vaccine
WO2006069911A3 (en) Mucoadhesive pharmaceutical compositions comprising chemoattractants
UA67251A (en) Strain paramixovirus-3 bovis "zksm" for the preparation of vaccines and diagnosticums
UA67250A (en) Strain bovinae herpesvirus-1 "moldavian" for the preparation of vaccines and diagnosticums
FR15C0080I2 (fr) Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
MY146370A (en) Classical swine fever tissue culture live vaccine virus, the tissue culture method of the same and classical swine fever tissue culture live vaccine comprising the same
HK1074847A (en) Infectious cdna of an approved vaccine strain of measles virus, use for immunogenic compositions